Thelansis

Wilson Disease (WD) Market Outlook Thelansis’s “Wilson Disease (WD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wilson Disease (WD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajectory? What...

Wilson Disease (WD) Market Outlook Thelansis’s “Wilson Disease (WD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Wilson Disease (WD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Wilson Disease (WD) Overview Wilson Disease (WD) is an inherited disorder characterized by an abnormality in copper metabolism. It results from specific mutations in the ATP7B gene, which encodes a protein called ATP7B responsible for copper transportation and regulation. This gene mutation can occur as homozygous or compounds heterozygous mutations. ATP7B plays a vital role in excreting excess copper into bile and facilitating the synthesis of c...

 Wilson Disease (WD) is an inherited disorder characterized by an abnormality in copper metabolism. It results from specific mutations in the ATP7B gene, which encodes a protein called ATP7B responsible for copper transportation and regulation. This gene mutation can occur as homozygous or compounds heterozygous mutations. ATP7B plays a vital role in excreting excess copper into bile and facilitating the synthesis of ceruloplasmin, a key copper-transporting protein in the bloodstream. The liver serves as the primary site for managing dietary copper, and in individuals with WD, impaired ATP7B function leads to copper accumulation within liver cells, causing liver-related issues. ·        The prevalence of Wilson's disease varies across regions, with around 31 to 37 cases per 100,000 individuals in EU countries, 48 to 59 cases in the USA, and 33 cases per 1,000,000 individuals in Japan.   Thelansis’s “Wilson Disease (WD) Market Outlook, Epidem...

 Wilson Disease (WD) is an inherited disorder of copper metabolism. The disease is caused by homozygous or compounds heterozygous mutations (the presence of two different mutant alleles) in ATP7B, which encodes transmembrane copper-transporting ATPase 2 (widely known as ATP7B), which mediates the excretion of copper into bile and delivers copper for the functional synthesis of ceruloplasmin (the major copper-transporting protein in the blood) diagnostic methods, ideal treatment regimens, efficacy evaluation standards and prognostic indicators for NPC. The liver is the site of metabolism for dietary copper; in WD, defective ATP7B function leads to copper overload in hepatocytes, which is associated with liver pathology. ·        Wilson disease (WD) prevalence ranges between 31 to 37 cases per 1,00,000 individuals in EU countries, 48 to 59 cases in the USA, and 33 cases per 1,000,000 individuals in Japan. ·        The gl...